Sponsored Links
| MDxHealth And Merck KGaA Extend Agreement For Use Of MGMT Assay In Brain Cancer Clinical Trials |
 |
 |
 |
| Medical News - Clinical Trials and Drug Trials | |||
|
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized medicine, announced today that it will extend its agreement with Merck KGaA, Darmstadt, Germany, for use of MDxHealth's MGMT assay in Merck KGaA's brain cancer clinical trials. Financial terms of the agreement are not disclosed... Read more: Clinical Trials / Drug Trials News From Medical News Today
|